[{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2023","type":"Private Placement","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0.22,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.22,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Danske Bank","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Danske Bank"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Oberland Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2021","type":"Financing","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.20000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Oberland Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Oberland Capital Management"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"DEKA Research & Development","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Hormone","year":"2021","type":"Collaboration","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Zealand Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Zealand Pharma"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2022","type":"Licensing Agreement","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zealand Pharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.040000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Novo Nordisk","highestDevelopmentStatusID":"15","companyTruncated":"Zealand Pharma \/ Novo Nordisk"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Novo Nordisk","highestDevelopmentStatusID":"15","companyTruncated":"Zealand Pharma \/ Novo Nordisk"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Glepaglutide","moa":"peptides: GLP peptide analogs","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Glepaglutide","moa":"peptides: GLP peptide analogs","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Zealand Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Zealand Pharma"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Private Placement","leadProduct":"Glepaglutide","moa":"peptides: GLP peptide analogs","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.10000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Danske Bank","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Danske Bank"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Private Placement","leadProduct":"Glepaglutide","moa":"peptides: GLP peptide analogs","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.10000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Danske Bank","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Danske Bank"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Glepaglutide","moa":"peptides: GLP peptide analogs","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Glepaglutide","moa":"peptides: GLP peptide analogs","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Glepaglutide","moa":"peptides: GLP peptide analogs","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Glepaglutide","moa":"peptides: GLP peptide analogs","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2022","type":"Private Placement","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Danske Bank","highestDevelopmentStatusID":"15","companyTruncated":"Zealand Pharma \/ Danske Bank"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP1R","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Carnegie Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Private Placement","leadProduct":"Survodutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.20999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Carnegie Investment Bank","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Carnegie Investment Bank"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GERMANY","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP1R","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Zealand Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Zealand Pharma"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Zealand Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Zealand Pharma"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Zealand Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Zealand Pharma"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Zealand Pharma \/ Zealand Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Zealand Pharma"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Parexel"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Zealand Pharma \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Parexel"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP1R","graph1":"Endocrinology","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP1R","graph1":"Endocrinology","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP1R","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Goldman Sachs International","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Dapiglutide","moa":"GLP-1R\/GLP-2R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0.90000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.90000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Goldman Sachs International","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Goldman Sachs International"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Goldman Sachs International","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Dapiglutide","moa":"GLP-1R\/GLP-2R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":1,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.90000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Goldman Sachs International","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Goldman Sachs International"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Dapiglutide","moa":"GLP-1R\/GLP-2R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Dapiglutide","moa":"GLP-1R\/GLP-2R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"ZP7570","moa":"GLP-1\/GLP-2 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Profil Institut f\u00fcr Stoffwechselforschung GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"ZP7570","moa":"GLP-1\/GLP-2 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Profil Institut f\u00fcr Stoffwechselforschung GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Pharma \/ Profil Institut f\u00fcr Stoffwechselforschung GmbH"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Profil Institut f\u00fcr Stoffwechselforschung GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Dapiglutide","moa":"GLP-1R\/GLP-2R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Zealand Pharma \/ Profil Institut f\u00fcr Stoffwechselforschung GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Profil Institut f\u00fcr Stoffwechselforschung GmbH"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Dapiglutide","moa":"GLP-1R\/GLP-2R","graph1":"Endocrinology","graph2":"Phase I","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Pharma \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Dapiglutide","moa":"GLP-1R\/GLP-2R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ZP9830","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Collaboration","leadProduct":"Petrelintide","moa":"||GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":5.2999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":5.2999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Novo Nordisk","highestDevelopmentStatusID":"15","companyTruncated":"Zealand Pharma \/ Novo Nordisk"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Hormone","year":"2023","type":"Private Placement","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zealand Pharma \/ Danske Bank","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Danske Bank"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Dapiglutide","moa":"GLP-1R\/GLP-2R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zealand Pharma \/ Zealand Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Zealand Pharma"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Glepaglutide","moa":"peptides: GLP peptide analogs","graph1":"Undisclosed","graph2":"Phase I","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Pharma \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Zealand Pharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
